Repligen Corporation
RGEN
Kedudukan dalam Saham
#1865
Repligen Corporation specializes in the creation and distribution of advanced... Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
Harga Saham
$179.36
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$11.39B
Perubahan (1 hari)
1.66%
Perubahan (1 tahun)
14.42%
Negara
US
Perdagangan Repligen Corporation (RGEN)
Kategori
Healthcare
Nisbah P/E bagi Repligen Corporation (RGEN)
Nisbah P/E pada October 2026 TTM: 240.81
Menurut laporan kewangan dan harga saham terkini Repligen Corporation, nisbah P/E semasa (TTM) ialah 240.81. Pada akhir 2023, syarikat mempunyai nisbah P/E sebanyak 281.45.
Sejarah nisbah P/E bagi Repligen Corporation dari 2000 hingga 2026
Nisbah P/E pada akhir setiap tahun
| Tahun | Nisbah P/E | Ubah |
|---|---|---|
| 2026 (TTM) | 240.81 | -176.31% |
| 2024 | -315.57 | -212.13% |
| 2023 | 281.45 | 457.38% |
| 2022 | 50.49 | -55.54% |
| 2021 | 113.57 | -32.42% |
| 2020 | 168.06 | -19.53% |
| 2019 | 208.85 | 50.35% |
| 2018 | 138.91 | 183.93% |
| 2017 | 48.92 | -44.77% |
| 2016 | 88.58 | -11.01% |
| 2015 | 99.54 | 26.39% |
| 2014 | 78.76 | 193.43% |
| 2013 | 26.84 | 95.70% |
| 2012 | 13.71 | -100.52% |
| 2011 | -2.65K | 8,512.40% |
| 2010 | -30.72 | -219.05% |
| 2009 | 25.81 | 544.33% |
| 2008 | 4.01 | -103.71% |
| 2007 | -107.95 | -167.49% |
| 2006 | 159.95 | -1,033.81% |
| 2005 | -17.13 | 81.87% |
| 2004 | -9.42 | -65.88% |
| 2003 | -27.60 | 18.19% |
| 2002 | -23.35 | 61.51% |
| 2001 | -14.46 | -73.38% |
| 2000 | -54.32 | 0.00% |
Nisbah P/E untuk syarikat serupa atau pesaing
| Syarikat | Nisbah P/E | Perbezaan Nisbah P/E | Negara |
|---|---|---|---|
| 47.48 | -80.28% |
US
|
|
| 27.43 | -88.61% |
FR
|
|
| - | - |
JP
|
|
| 56.89 | -76.37% |
US
|
|
| - | - |
CH
|
Cara membaca nisbah P/E
Nisbah Harga/Perolehan (P/E) mengukur hubungan antara harga saham syarikat dan pendapatan sesaham.
P/E yang rendah tetapi positif menunjukkan syarikat menjana keuntungan tinggi berbanding dengan penilaian semasa dan mungkin dinilai rendah. P/E negatif yang tinggi (hampir 0) menunjukkan kerugian besar.
Syarikat dengan P/E melebihi 30 atau negatif biasanya dilihat sebagai "saham pertumbuhan", bermaksud pelabur menjangkakan pertumbuhan atau keuntungan masa depan.
Syarikat dengan P/E positif di bawah 10 biasanya dianggap sebagai "saham nilai", bermaksud syarikat sudah menguntungkan dan tidak dijangka berkembang pesat.